Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors Comprehensive next-generation sequencing platforms provide tumor genomic ...
To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results